Design of nanoparticle structures for cancer immunotherapy

Peter Tsirikis, Sue Dong Xiang, Cordelia Selomulya, Magdalena Plebanski

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

1 Citation (Scopus)

Abstract

Cancer is the leading cause of death worldwide. Central to an effective immunotherapeutic treatment is the generation of CD8+ cytotoxic T lymphocyte responses to the malignant cells. Dendritic cells (DCs) are the key target in cancer immunotherapy. DCs recognize pathogens, initiate the immune response, and are capable of cross-presentation for the induction of CD8 T cell responses. DC-based cancer immunotherapies have been in trials in humans. Nanoparticles, as a vaccine carrier, have shown efficacy in antigen delivery by directly targeting DCs. This chapter examines how prophylactic and therapeutic tumor immunities can be achieved using nanoparticles targeting DCs in vivo. Moreover, this review elucidates the differential immunological properties of engineered nanoparticles. Surface morphology, size, shape, and surface functionalization can influence cellular uptake, toxicity, immunogenicity, and the T-helper 1 (Th1)/T-helper 2 (Th2) bias of the immune response. Understanding how nanoparticles with finely tuned properties interact and modulate the immune response will drive the logical development of nanoparticle vaccines to achieve the intended immunological response.

Original languageEnglish
Title of host publicationNanostructures for Cancer Therapy
EditorsAnton Ficai, Alexandru Mihai Grumezescu
Place of PublicationAmsterdam Netherlands
PublisherElsevier
Pages307-328
Number of pages22
ISBN (Electronic)9780323461504
ISBN (Print)9780323461443
DOIs
Publication statusPublished - 14 Apr 2017

Publication series

NameNanostructures in Therapeutic Medicine Series
PublisherElsevier
Volume4

Keywords

  • Adjuvant
  • Cancer immunotherapy
  • Carrier
  • CD8 T cell responses
  • Dendritic cells
  • Nanoparticle
  • Roughness
  • Shape
  • Size
  • Surface functionalization
  • Vaccine delivery

Cite this

Tsirikis, P., Xiang, S. D., Selomulya, C., & Plebanski, M. (2017). Design of nanoparticle structures for cancer immunotherapy. In A. Ficai, & A. M. Grumezescu (Eds.), Nanostructures for Cancer Therapy (pp. 307-328). (Nanostructures in Therapeutic Medicine Series; Vol. 4). Amsterdam Netherlands: Elsevier. https://doi.org/10.1016/B978-0-323-46144-3.00012-X
Tsirikis, Peter ; Xiang, Sue Dong ; Selomulya, Cordelia ; Plebanski, Magdalena. / Design of nanoparticle structures for cancer immunotherapy. Nanostructures for Cancer Therapy. editor / Anton Ficai ; Alexandru Mihai Grumezescu. Amsterdam Netherlands : Elsevier, 2017. pp. 307-328 (Nanostructures in Therapeutic Medicine Series).
@inbook{52caa99470c64c119481d6321a2ee890,
title = "Design of nanoparticle structures for cancer immunotherapy",
abstract = "Cancer is the leading cause of death worldwide. Central to an effective immunotherapeutic treatment is the generation of CD8+ cytotoxic T lymphocyte responses to the malignant cells. Dendritic cells (DCs) are the key target in cancer immunotherapy. DCs recognize pathogens, initiate the immune response, and are capable of cross-presentation for the induction of CD8 T cell responses. DC-based cancer immunotherapies have been in trials in humans. Nanoparticles, as a vaccine carrier, have shown efficacy in antigen delivery by directly targeting DCs. This chapter examines how prophylactic and therapeutic tumor immunities can be achieved using nanoparticles targeting DCs in vivo. Moreover, this review elucidates the differential immunological properties of engineered nanoparticles. Surface morphology, size, shape, and surface functionalization can influence cellular uptake, toxicity, immunogenicity, and the T-helper 1 (Th1)/T-helper 2 (Th2) bias of the immune response. Understanding how nanoparticles with finely tuned properties interact and modulate the immune response will drive the logical development of nanoparticle vaccines to achieve the intended immunological response.",
keywords = "Adjuvant, Cancer immunotherapy, Carrier, CD8 T cell responses, Dendritic cells, Nanoparticle, Roughness, Shape, Size, Surface functionalization, Vaccine delivery",
author = "Peter Tsirikis and Xiang, {Sue Dong} and Cordelia Selomulya and Magdalena Plebanski",
year = "2017",
month = "4",
day = "14",
doi = "10.1016/B978-0-323-46144-3.00012-X",
language = "English",
isbn = "9780323461443",
series = "Nanostructures in Therapeutic Medicine Series",
publisher = "Elsevier",
pages = "307--328",
editor = "Anton Ficai and Grumezescu, {Alexandru Mihai}",
booktitle = "Nanostructures for Cancer Therapy",
address = "Netherlands",

}

Tsirikis, P, Xiang, SD, Selomulya, C & Plebanski, M 2017, Design of nanoparticle structures for cancer immunotherapy. in A Ficai & AM Grumezescu (eds), Nanostructures for Cancer Therapy. Nanostructures in Therapeutic Medicine Series, vol. 4, Elsevier, Amsterdam Netherlands, pp. 307-328. https://doi.org/10.1016/B978-0-323-46144-3.00012-X

Design of nanoparticle structures for cancer immunotherapy. / Tsirikis, Peter; Xiang, Sue Dong; Selomulya, Cordelia; Plebanski, Magdalena.

Nanostructures for Cancer Therapy. ed. / Anton Ficai; Alexandru Mihai Grumezescu. Amsterdam Netherlands : Elsevier, 2017. p. 307-328 (Nanostructures in Therapeutic Medicine Series; Vol. 4).

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

TY - CHAP

T1 - Design of nanoparticle structures for cancer immunotherapy

AU - Tsirikis, Peter

AU - Xiang, Sue Dong

AU - Selomulya, Cordelia

AU - Plebanski, Magdalena

PY - 2017/4/14

Y1 - 2017/4/14

N2 - Cancer is the leading cause of death worldwide. Central to an effective immunotherapeutic treatment is the generation of CD8+ cytotoxic T lymphocyte responses to the malignant cells. Dendritic cells (DCs) are the key target in cancer immunotherapy. DCs recognize pathogens, initiate the immune response, and are capable of cross-presentation for the induction of CD8 T cell responses. DC-based cancer immunotherapies have been in trials in humans. Nanoparticles, as a vaccine carrier, have shown efficacy in antigen delivery by directly targeting DCs. This chapter examines how prophylactic and therapeutic tumor immunities can be achieved using nanoparticles targeting DCs in vivo. Moreover, this review elucidates the differential immunological properties of engineered nanoparticles. Surface morphology, size, shape, and surface functionalization can influence cellular uptake, toxicity, immunogenicity, and the T-helper 1 (Th1)/T-helper 2 (Th2) bias of the immune response. Understanding how nanoparticles with finely tuned properties interact and modulate the immune response will drive the logical development of nanoparticle vaccines to achieve the intended immunological response.

AB - Cancer is the leading cause of death worldwide. Central to an effective immunotherapeutic treatment is the generation of CD8+ cytotoxic T lymphocyte responses to the malignant cells. Dendritic cells (DCs) are the key target in cancer immunotherapy. DCs recognize pathogens, initiate the immune response, and are capable of cross-presentation for the induction of CD8 T cell responses. DC-based cancer immunotherapies have been in trials in humans. Nanoparticles, as a vaccine carrier, have shown efficacy in antigen delivery by directly targeting DCs. This chapter examines how prophylactic and therapeutic tumor immunities can be achieved using nanoparticles targeting DCs in vivo. Moreover, this review elucidates the differential immunological properties of engineered nanoparticles. Surface morphology, size, shape, and surface functionalization can influence cellular uptake, toxicity, immunogenicity, and the T-helper 1 (Th1)/T-helper 2 (Th2) bias of the immune response. Understanding how nanoparticles with finely tuned properties interact and modulate the immune response will drive the logical development of nanoparticle vaccines to achieve the intended immunological response.

KW - Adjuvant

KW - Cancer immunotherapy

KW - Carrier

KW - CD8 T cell responses

KW - Dendritic cells

KW - Nanoparticle

KW - Roughness

KW - Shape

KW - Size

KW - Surface functionalization

KW - Vaccine delivery

UR - http://www.scopus.com/inward/record.url?scp=85040630788&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-46144-3.00012-X

DO - 10.1016/B978-0-323-46144-3.00012-X

M3 - Chapter (Book)

SN - 9780323461443

T3 - Nanostructures in Therapeutic Medicine Series

SP - 307

EP - 328

BT - Nanostructures for Cancer Therapy

A2 - Ficai, Anton

A2 - Grumezescu, Alexandru Mihai

PB - Elsevier

CY - Amsterdam Netherlands

ER -

Tsirikis P, Xiang SD, Selomulya C, Plebanski M. Design of nanoparticle structures for cancer immunotherapy. In Ficai A, Grumezescu AM, editors, Nanostructures for Cancer Therapy. Amsterdam Netherlands: Elsevier. 2017. p. 307-328. (Nanostructures in Therapeutic Medicine Series). https://doi.org/10.1016/B978-0-323-46144-3.00012-X